RecruitingNCT06856343
REBECCA Real-world Early BrEast CanCer mAnagement
REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
Sponsor
AstraZeneca
Enrollment
126 participants
Start Date
Dec 30, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Male or female aged ≥ 18 years
- Patient diagnosed with HER2-negative eBC
- Patient about to be initiated with adjuvant Olaparib at their physician's discretion
- Patient has been informed and does not object to participation in the study.
Exclusion Criteria2
- Patient not consenting to participate.
- Patients included in the Early Access Program
Locations(44)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06856343
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location